Inhibrx Inc. Common Stock is a biotechnology company that specializes in the discovery and development of novel antibodies for the treatment of cancer and other diseases. With a strong focus on scientific innovation and cutting-edge technology, Inhibrx aims to revolutionize the field of immunotherapy and improve patient outcomes. Their extensive pipeline of drug candidates and strategic partnerships position them as a leader in the industry.
Notification